NCT02124824View on ClinicalTrials.gov

Contribution of Endothelin-1 to Exercise Intolerance in Heart Failure

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2014

Primary Completion Date

March 31, 2019

Study Completion Date

March 31, 2019

Conditions
Heart Failure
Interventions
DRUG

BQ-123

Endothelin subtype A antagonist

Trial Locations (1)

84148

VA Salt Lake City Health Care System, Salt Lake City, UT, Salt Lake City

All Listed Sponsors
collaborator

University of Utah

OTHER

lead

VA Office of Research and Development

FED

NCT02124824 - Contribution of Endothelin-1 to Exercise Intolerance in Heart Failure | Biotech Hunter | Biotech Hunter